<DOC>
	<DOCNO>NCT00654745</DOCNO>
	<brief_summary>To determine olmesartan plus amlodipine combination therapy alone hydrochlorothiazide safe effective reduce high blood pressure hypertensive , type 2 diabetic subject .</brief_summary>
	<brief_title>18 Week Study Evaluating Safety Efficacy Olmesartan , Amlodipine , Hydrochlorothiazide , Type 2 Diabetics</brief_title>
	<detailed_description>This single group study participant titrate next 6 regimen blood pressure ( BP ) goal meet .</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine Besylate , Olmesartan Medoxomil Drug Combination</mesh_term>
	<criteria>Males female age 18 80 year . Diagnosis type 2 diabetes mellitus stable regimen oral antidiabetic agent ( ) least 3 month , without adjunctive use Byetta ( exenatide ) ; Note : Subjects diagnose type 2 diabetes mellitus oral antidiabetic agent may enrol documented history type 2 diabetes American Diabetes Association criterion , include specific plasma glucose result list : Fasting plasma glucose &gt; =126 mg/dL ( 7.0 mmol/L ) ; Symptoms hyperglycemia casual ( time day without regard time since last meal ) plasma glucose &gt; =200 mg/dL ( 11.1 mmol/L ) . The classic symptom hyperglycemia consider include polyuria , polydipsia , unexplained weight loss ; Twohour plasma glucose &gt; =200 mg/dL ( 11.1 mmol/L ) oral glucose tolerance test ; Newly diagnose hypertension uncontrolled hypertension ( define SBP &gt; 130 mmHg and/or DBP &gt; 80 mmHg ) current antihypertensive monotherapy combination therapy . Subjects must fulfill mean seated office blood pressure parameter two consecutive , qualify visit placebo runin phase , , subsequently , daytime ambulatory blood pressure monitoring ( ABPM ) criterion . Females pregnant lactating , applicable , use adequate contraception . Subjects uncontrolled hypertension take multiple antihypertensive therapy ( discretion investigator ) . Type 2 diabetes mellitus glycosylated hemoglobin A1c ( HbA1c ) &gt; =9.0 % screening ; Subjects type 1 type 2 diabetes mellitus require insulin . Subjects serious disorder may limit ability evaluate safety efficacy study medication , subject secondary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>blood pressure reduction</keyword>
</DOC>